Persistent Systems Ltd
Q2 FY25 Earnings Call Analysis
IT - Software
fundraise: No informationcapex: No informationrevenue: Category 3margin: Category 2orderbook: Yes
💰fundraise
Any current/future new fundraising through debt or equity?
- There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript/pages.
- The company has not discussed raising new capital via debt or equity in the recent earnings call or disclosures.
- Focus remains on operational growth, margin improvement, large deal pipelines, and cautious cost management.
- Debt, cash, and investments appear stable, with total cash and investments at Rs. 307.8 million as of June 30, 2025.
- No forward-looking statements indicate plans for external fundraising at this time.
🏗️capex
Any current/future capex/capital investment/strategic investment?
- The transcript does not explicitly mention specific current or future capex (capital expenditures) plans.
- Persistent Systems is focusing on strategic investments primarily in AI capabilities and platform development, including their generative AI-powered digital engineering platform, SASVA 3.0.
- The company acquired Arrka last year, which strengthened their Digital Trust Layer capabilities integrated across platforms like SASVA, iAURA, and GenAI Hub.
- Investment is also being made in talent transformation and building AI-enabled workforce, highlighted by organizational changes such as hiring a new Chief Marketing Officer and Chief People Officer.
- There is mention of maintaining investments in SG&A and operational initiatives, implying ongoing strategic spend to support growth.
- No detailed capex or capital investment figures or plans are disclosed within the provided transcript.
📊revenue
Future growth expectations in sales/revenue/volumes?
- Persistent Systems is confident of continuing growth across key verticals, targeting top-quartile growth in the sector.
- The BFSI (Banking, Financial Services and Insurance) segment is expected to lead growth for the year, followed by high-tech and healthcare life sciences.
- Healthcare vertical will continue to grow, though not at the elevated rates of the past year; no further degrowth expected.
- The company aims to reach a $2 billion revenue run-rate by the end of FY27.
- Pipeline and order book remain healthy, though decision-making is cautious due to macroeconomic factors.
- Larger deals are in the pipeline, creating potential upside in future sales.
- Revenue conversion focuses on ACV from multi-year deals, illustrating steady contractual growth.
- Management remains prudent, deferring wage hikes to navigate current uncertainties.
- No specific forward-looking guidance numbers given, but overall outlook is positive with continued investment in AI capabilities and sales channels.
📈margin
Future growth expectations in earnings/operating earnings/profits/EPS?
- Persistent Systems aims to reach a $2 billion revenue run rate by the end of FY27, indicating strong growth expectations.
- EBIT margin is expected to improve by 200-300 basis points by FY27 from ~15% in Q1 FY26.
- ESOP costs, which impacted margins recently, are expected to remain flat before gradually reducing in FY27.
- Revenue growth is expected to be led by BFSI, followed by software high-tech and healthcare life sciences verticals, all projecting growth.
- Trailing 12-month attrition and other costs are being managed prudently to support margin expansion.
- EPS grew 36.5% YoY in Q1 FY26; continued profit growth reflects operational leverage and better collections.
- Persistent maintains a confident stance on margin trajectory with operational efficiency and pricing initiatives driving future profits.
- No specific forward guidance provided on quarterly earnings, but the overall tone is confident in achieving top-quartile industry growth.
📋orderbook
Current/ Expected Orderbook/ Pending Orders?
- Total Contract Value (TCV) for Q1 FY26 stood at USD 520.8 million.
- New bookings contributed TCV of USD 337.0 million.
- Annual Contract Value (ACV) of this TCV is USD 385.3 million.
- ACV from new bookings contributed USD 211.8 million.
- Management is reasonably confident about the growth journey and executable order book.
- Pipeline and order book are described as healthy despite a cautious market environment.
- Longer decision-making cycles noted, requiring a larger pipeline to maintain bookings.
- No specific forward-looking guidance given on order book growth, but larger deal pipelines are present.
- Management will let future quarters unfold before giving concrete updates on order book and deal wins.
